Provectus Biopharmaceuticals filings document governance, capital-structure actions, and material-event disclosures for a clinical-stage biotechnology issuer focused on rose bengal sodium-based medicines. Proxy materials cover annual-meeting voting matters, board elections, stock ownership, director and officer interests, and related-party transaction disclosures.
Form 8-K reports record corporate events such as annual-meeting announcements and amendments to the certificates of designation for Series D and Series D-1 Convertible Preferred Stock. These filings also describe preferred-stock conversion terms, common-stock implications, exhibit filings, and the company’s use of press releases to furnish updates tied to public-company reporting.
Provectus Biopharmaceuticals (PVCT) CEO and director reported acquiring an 8% unsecured convertible promissory note on 11/13/2025. The note’s outstanding principal and interest may be converted into Series D-1 Convertible Preferred Stock at $2.862 per share, and will automatically convert at that price twelve months after the issue date.
Table II lists an underlying amount of 10,483 shares of Series D-1 Preferred. Each Series D-1 Preferred share is convertible into 10 shares of common stock. The Series D-1 Preferred will automatically convert into common stock on June 26, 2026, unless converted earlier under its terms.
Provectus Biopharmaceuticals (PVCT) reported Q3 2025 results with continued operating losses and very limited liquidity. Net loss was $1.32 million for the quarter and $4.34 million for the nine months ended September 30, 2025. Cash was $72,479 as of September 30, 2025, and management stated these conditions raise substantial doubt about the company’s ability to continue as a going concern.
The company used $2.46 million in operating cash flow year‑to‑date and reported a working capital deficit of $6.19 million as of September 30, 2025. To fund operations, Provectus raised $1.525 million in unsecured 2025 convertible notes during the nine months, which bear 8% interest and automatically convert to Series D‑1 Preferred Stock after 12 months at $2.862 per share; each Series D‑1 share is convertible into 10 common shares.
The company also converted prior‑period notes into equity, issuing 869,415 Series D‑1 Preferred shares during the nine months. Common shares outstanding were 420,279,879 as of November 12, 2025. Operating expenses rose, led by general and administrative costs and stock‑based compensation, while grant revenue concluded by mid‑2025.
Provectus Biopharmaceuticals (PVCT) CEO and director Edward Pershing filed a Form 4 reporting an insider transaction on 11/06/2025. He acquired an 8% unsecured convertible promissory note issued under the company’s 2025 Financing.
The note may be converted into Series D‑1 Convertible Preferred Stock at $2.862 per share, and will automatically convert twelve months after the issue date. The filing lists 12,230 shares of Series D‑1 Preferred as the securities underlying the note. Each Series D‑1 Preferred share is convertible into 10 shares of common stock, and the preferred automatically converts to common on June 26, 2026 unless converted earlier.
Provectus Biopharmaceuticals (PVCT) CEO and Director Edward Pershing reported acquiring an 8% unsecured convertible promissory note with a principal amount of $65,000 on 10/30/2025.
The note is convertible at a price of $2.862 per share into Series D-1 Convertible Preferred Stock, representing 22,712 preferred shares. The note’s outstanding principal and interest will automatically convert into Series D-1 Preferred at $2.862 on the date that is twelve months after issuance. Each Series D-1 Preferred share converts into 10 shares of common stock and will automatically convert into common stock on June 26, 2026, unless converted earlier per its terms.
Following the reported transaction, $1,180,000 of derivative securities were beneficially owned, held directly.
Provectus Biopharmaceuticals (PVCT) CEO and director Edward Pershing reported a transaction on 10/23/2025 involving an 8% unsecured convertible promissory note. The note may be converted at a price of $2.862 per share into Series D-1 Convertible Preferred Stock.
The outstanding principal and interest of the note will automatically convert into Series D-1 Preferred twelve months after the issue date. Each share of Series D-1 Preferred is convertible into 10 shares of common stock, and the Series D-1 Preferred will automatically convert into common stock on June 26, 2026, unless converted earlier according to its terms.
Provectus Biopharmaceuticals (PVCT) CEO and director reported a non-cash conversion on 10/16/2025. An 8% unsecured convertible promissory note issued in 2024 converted into 18,880 shares of Series D-1 Convertible Preferred Stock at a conversion price of $2.862 per preferred share. Each preferred share is convertible into 10 common shares, equating to 188,800 underlying common shares. The Series D-1 Preferred will automatically convert into common stock on June 20, 2026, unless converted earlier.
Provectus Biopharmaceuticals (PVCT) reported an insider transaction by its CEO and Director. On 10/10/2025, the reporting person acquired an 8% unsecured convertible promissory note. The note is convertible at $2.862 per share into Series D-1 Convertible Preferred Stock, with 20,965 preferred shares shown as the underlying amount. The note’s outstanding principal and interest will automatically convert into Series D-1 Preferred twelve months after its issue date. Each Series D-1 Preferred share converts into 10 common shares and will automatically convert into common stock on June 26, 2026, unless converted earlier per its terms.
Edward Pershing, CEO and director of Provectus Biopharmaceuticals, Inc. (PVCT), reported a securities transaction on 10/03/2025. He acquired an 8% unsecured convertible promissory note with a principal amount of $35,000 that is convertible into Series D-1 Convertible Preferred Stock at a fixed conversion price of $2.862 per share. The Note may be voluntarily converted any time while outstanding and will automatically convert into Series D-1 Preferred Stock twelve months after issuance on 10/03/2026. The filing shows 12,230 shares of Series D-1 Preferred Stock reported as beneficially owned after the transaction and a stated aggregate amount of $1,085,000 associated with that class. Each share of Series D-1 Preferred Stock is convertible into 10 shares of common stock and will automatically convert into common stock on 6/26/2026 unless earlier converted.
Edward Pershing, CEO and Director of Provectus Biopharmaceuticals (PVCT), converted an 8% unsecured convertible promissory note issued under the company's 2024 financing into preferred and common shares. The $175,000 2024 Note converted on 09/30/2025 into 66,052 shares of Series D-1 Convertible Preferred Stock at a conversion price of $2.862 per share. Each Series D-1 share is convertible into 10 shares of common stock, producing 660,520 common shares underlying the preferred shares. The filing shows 2,484,499 shares of common stock beneficially owned following the reported transactions. The Series D-1 automatically converts into common stock on 06/20/2026 unless earlier converted under its terms.
Edward Pershing, CEO and Director of Provectus Biopharmaceuticals, Inc. (PVCT), converted a 2024 unsecured convertible promissory note into equity on September 19, 2025. The $100,000 8% note, originally issued under the companys 2024 financing and convertible at $2.862 per share into Series D-1 Preferred Stock, converted into 37,760 shares of Series D-1 Preferred Stock on that date. Each Series D-1 share is convertible into ten shares of common stock, so the conversion corresponds to 377,600 shares of common stock. Following the transaction, Mr. Pershing beneficially owned 2,418,447 shares of common stock. The Series D-1 will automatically convert to common on June 20, 2026 unless earlier converted under its terms.
Edward Pershing, CEO and Director of Provectus Biopharmaceuticals, Inc. (PVCT), converted a 2024 unsecured convertible promissory note into equity on September 19, 2025. The $100,000 8% note, originally issued under the companys 2024 financing and convertible at $2.862 per share into Series D-1 Preferred Stock, converted into 37,760 shares of Series D-1 Preferred Stock on that date. Each Series D-1 share is convertible into ten shares of common stock, so the conversion corresponds to 377,600 shares of common stock. Following the transaction, Mr. Pershing beneficially owned 2,418,447 shares of common stock. The Series D-1 will automatically convert to common on June 20, 2026 unless earlier converted under its terms.